AbbVie's blood cancer drug meets late-stage trial goals
ABBV•Late-stage trial result
AbbVie ABBV.N said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
Related News
Nasdaq Trade Halt Continues <UCFIW.O> Reason Not Available at 09:32 AM
UCFIW•
Strategy, Google Cloud launch seven-city AI Transformation Forum series
MSTR•
Broadcom Inc <AVGO.O>: BofA Global Research cuts price objective to $460 from $530
AVGO•
UK electric car sales jump 30% in August to lead market, data shows
TSLA•
Haleon secures better shelf space at Walmart, Target in bid to boost market share
HLN•